Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance

American Journal of Physiology - Endocrinology and Metabolism

Volumn 287, Issue 5 50-5, 2004, Pages

  Chang, Annette M ^a   Smith, Maria J ^a   Bloem, Cathie J ^a   Galecki, Andrzej T ^b   Halter, Jeffrey B ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

cell function; Aged humans; Glucose intolerance

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; INSULIN; PLACEBO;

ADULT; AGE; AGED; AGING; ARTICLE; BODY MASS; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 6044253702     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00156.2004     Document Type: Article

References (31)

1. Barrett-Connor E and Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care 21: 1236-1239, 1998.
2. Basu R, Breda E, Oberg A, Powell CC, Man CD, Basu A, Vittone JL, Klee GG, Arora P, Jensen MD, Toffolo G, Cobellia D, and Rizza R. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 52: 1738-1748, 2003.
3. Bergman RN. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes 38: 1512-1527, 1989.
4. Bergman RN, Phillips LS, and Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456-1467, 1981.
5. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez P J PJ, Calle JR, and Maranes JP. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab 22: 201-202, 1996.
6. Chang AM and Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 284: E7-E12, 2003.
7. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, and Halter JB. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52: 1786-1791, 2003.
8. Chang AM, Smith MJ, Bloem CJ, and Halter JB. Impaired beta-cell adaptation to insulin resistance in older humans. Diabetes 52, Suppl 1: A28, 2003.
9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077, 2002.
10. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, and Wolever TM. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19: 1190-1193, 1996.
11. DECODE Study Group. Consequences of the new diagnostic criteria for diabetes in older men and women. Diabetes Care 22: 1667-1671, 1999.
12. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, and DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47: 31-39, 2004.
13. Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Metabolism 46: 40-43, 1997.
14. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, and Fucker K. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14: 732-737, 1991.
15. Harris MI, Hadden WC, Knowler WC, and Bennett PH. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The third National Health and Nutrition Examination Survey, 1988-1994. Diabetes 21: 518-524, 1998.
16. Hidaka H, Nagulesparan M, Klimes I, Clark R, Haruka S, Aronoff SL, Vasquez B, Rubensein AH, and Unger R. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J Clin Endocrinol Metab 54: 217-222, 1982.
17. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, and Sakamoto N. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med 10: 134-138, 1993.
18. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, and D'Embden H. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 16: 499-502, 1993.
19. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, and Porte D. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
20. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, and Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. New Engl J Med 329: 1988-1992, 1993.
21. Meneilly GS, Ryan EA, Radziuk J, Lau DCW, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, and Elahi D. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 23: 1162-1167, 2000.
22. Meyer J, Sturis J, Katschinski M, Arnold R, Goke B, and Byrne M. Acute hyperglycemia alters the ability of the normal β-cell to sense and respond to glucose. Am J Physiol Endocrinol Metab 282: E917-E922, 2002.
23. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, and Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13, Suppl 3: 32-36, 1990.
24. Resnick HE, Harris MI, Brock DB, and Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles. Diabetes Care 23: 176-180, 2000.
25. Rosetti L, Giaccari A, and DeFronzo RA. Glucose toxicity. Diabetes Care 13: 610-630, 1990.
26. Schnack C, Prager RJ, Winkler J, Klauser RM, Schneider BG, and Schernthaner G. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12: 537-543, 1989.
27. Vague P and Moulin JP. The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metabolism 31: 139-142, 1982.
28. Van Cauter E, Mestrez F, Sturis J, and Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368-377, 1992.
29. Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, and Tracy RP. Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet 352: 1012-1015, 1998.
30. Weyer C, Bogardus C, Mott DM, and Pratley R. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794, 1999.
31. Yang YJ, Youn JH, and Bergman RN. Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol Endocrinol Metab 253: E595-E602, 1987.